No. of Recommendations: 1
And a slightly less postivie, but still price gain from here, from Wells:
'24 Recovery May be Weaker Than Expected; Remain on the Sidelines: The fact that
earnings risk seems low is important, and we are tempted by the stock here, but key
questions remain since we are not convinced the pivot was decisive enough. There are
one-time issues in the '23 guidance, but there are also growth challenges ahead (weak
comps, continued labor pressure, no share repo). We now see fair value at $145 (down
from $165), about 17x our $8.50 2024 estimate. Remain Equal Weight.
